Why is Ionis Pharmaceuticals stock up 3% today?
Ionis Pharmaceuticals, Inc. (IONS) is up 3.03% today as buyers respond to ongoing momentum after the company received EU approval for its RNA-targeted therapy Tryngolza (olezarsen) to treat severe hypertriglyceridemia. The rebound looks limited, with Ionis Pharmaceuticals still trading below the 20-day, 50-day, and 200-day moving averages.
Highlights
- Ionis Pharmaceuticals received EU approval for Tryngolza in severe hypertriglyceridemia, with a label expansion set for November 2026.
- Third-quarter revenues for Tryngolza missed estimates and Ionis lowered its sales guidance, with multiple law firms announcing investor investigations.
- Ionis Pharmaceuticals stock trades below key moving averages, with technical indicators showing pronounced weakness and a 78% probability of a move to $26.08 to $29.4 over the next five days.
Muted investor confidence as sales miss triggers regulatory scrutiny
Ionis Pharmaceuticals received EU approval for Tryngolza (olezarsen) in adults with severe hypertriglyceridemia, with the European Commission granting a label expansion in November 2026. The company reported third-quarter revenues for Tryngolza that fell short of expectations, which led Ionis to lower its sales guidance for the drug. Law firms, including Bronstein, Gewirtz & Grossman, announced investigations into Ionis Pharmaceuticals on behalf of investors. The company also highlighted ongoing launches of three new medicines at the Jefferies Global Healthcare Conference, confirming that it now has seven products on the market for eight disease indications.
Persistent selling pressure as momentum indicators confirm broad weakness
Ionis Pharmaceuticals is trading below the 20-day, 50-day, and 200-day moving averages ($37.51, $42.47, and $63.95), indicating persistent downside pressure from sellers in short, medium, and long-term views. The nearest resistance is at $29.4, with today’s high at $27.68 acting as the closest support; the moving average alignment confirms a broadly bearish long-term trend. Momentum indicators signal pronounced weakness: MACD and Average Directional Index (ADX) both favor continued selling pressure. Relative Strength Index (RSI), Stochastic RSI, and Commodity Channel Index (CCI) each register in their oversold zones, suggesting the stock is at an extreme that may precede a potential technical rebound but does not guarantee one. Sellers currently dominate intraday momentum according to Bull/Bear Power (BBP), with the Awesome Oscillator neutral. Intraday volatility stands at 3.67%, reflecting strength toward session highs despite momentum indicators remaining bearish overall.
Earlier, analysts noted that Ionis Pharmaceuticals was experiencing persistent bearish momentum, with technical indicators and price action emphasizing continued downside risk. The current setup strengthens that outlook, with sustained selling pressure and recent volatility underscoring $29.4 as a key resistance level that traders should monitor closely for signs of a potential technical rebound or renewed decline.